ChiCTR2200060919 版本V1.1 版本创建时间2023/03/30 00:24:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200060919 

最近更新日期:

Date of Last Refreshed on:

2022-06-14 15:41:52 

注册时间:

Date of Registration:

2022-06-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

全民战疫:基于虚拟交互培训系统干预的随机对照试验方案,以改善公众对重大突发传染病的应急准备

Public title:

People’s War Against Pandemic: protocol for a randomized control trial based on a virtual interactive training system intervention to improve the emergency preparedness of public for major emerging infectious diseases

注册题目简写:

全民战疫干预的随机对照试验方案

English Acronym:

A randomized control trial of People’s War Against Pandemic

研究课题的正式科学名称:

重大突发传染病公众应急准备度虚拟交互科普培训系统的开发

Scientific title:

Development of a virtual interactive popular science training system for public emergency preparedness of major emerging infectious

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

罗月 

研究负责人:

陈燕华 

Applicant:

Luo Yue 

Study leader:

Chen Yanhua 

申请注册联系人电话:

Applicant telephone:

18383079861

研究负责人电话:

Study leader's
telephone:

18982765016

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1982192341@qq.com

研究负责人电子邮件:

Study leader's E-mail:

chen_yanhua25@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省泸州市西南医科大学城北校区

研究负责人通讯地址:

四川省泸州市太平街25号

Applicant address:

Chengbei campus of Southwest Medical University, Luzhou City, Sichuan Province

Study leader's address:

25, Taiping Road, Luzhou City, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西南医科大学

Applicant's institution:

Southwest Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2022001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西南医科大学附属医院临床试验伦理委员会

Name of the ethic committee:

Ethics Committee of Clinical Trials, Affiliated Hospital of Southwest Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-01-04 00:00:00

伦理委员会联系人:

张增瑞

Contact Name of the ethic committee:

Zhang Zengrui

伦理委员会联系地址:

四川省泸州市太平街25号

Contact Address of the ethic committee:

25, Taiping Road, Luzhou City, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西南医科大学附属医院

Primary sponsor:

The Affiliated Hospital of Southwest Medical University

研究实施负责(组长)单位地址:

四川省泸州市太平街25号

Primary sponsor's address:

25, Taiping Road, Luzhou City, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

泸州

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属医院

具体地址:

四川省泸州市太平街25号

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Address:

25, Taiping Road, Luzhou, Sichuan

经费或物资来源:

四川省科技计划项目

Source(s) of funding:

Sichuan Science and Technology Program

研究疾病:

重大突发传染病  

Target disease:

Major emerging infectious diseases

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

应用重大突发传染病下公众应急准备度虚拟交互科普培训系统提高重大突发传染病下公众应急准备度,使公众能有效应对重大突发传染病并从中恢复。  

Objectives of Study:

The virtual interactive training system for public emergency preparedness of major emerging infectious diseases is applied to improve the public emergency preparedness, so that the public can effectively respond to and recover from major emerging infectious diseases.

药物成份或治疗方案详述:

参与者需要每天至少完成一次故事线任务,在知识角观看至少一篇文章和一篇视频,并在智能评估模块中完成对错误选择的重新测试。研究人员通过用户管理模块检查参与者的完成情况,那些没有完成的人将通过发送短信或电话得到提醒。 

Description for medicine or protocol of treatment in detail:

Participants need to complete the storyline task at least once a day, watch at least one article and one video in the knowledge corner, and complete a retest of wrong choices in the intelligent evaluation module. Researchers check the completion of participants through the user management module, and those who fail to complete will be reminded by sending text messages or phone. 

纳入标准:

①年龄在16至60岁之间;
②参与者意识清晰,无精神障碍,能够上网,能够使用电脑或智能手机;
③参与者签署知情同意书并自愿参与研究。

Inclusion criteria

1) public aged 16-60; 2) Participants have clear consciousness, no mental disorders, and have access to the Internet and be able to use computers or smart phones; 3) Participants sign informed consent and voluntarily participate in the study.

排除标准:

①不能配合完成相关结局指标评估者;
②正参与其它试验者

Exclusion criteria:

1) Ongoing or already on emergency preparedness for MEIDs intervention; 2) Unable to cooperate to complete the evaluation of relevant outcome indicators.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2022-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-01 00:00:00 To 2022-08-31 00:00:00

干预措施:

Interventions:

组别:

全民战疫干预组1

样本量:

206

Group:

The People’s War Against Pandemic intervention group 1

Sample size:

干预措施:

使用全民战疫虚拟交互培训系统干预2周

干预措施代码:

Intervention:

The People’s War Against Pandemic virtual interactive training system will be used for two weeks

Intervention code:

组别:

全民战疫干预组2

样本量:

206

Group:

The People’s War Against Pandemic intervention group 2

Sample size:

干预措施:

使用全民战疫虚拟交互培训系统干预4周

干预措施代码:

Intervention:

The People’s War Against Pandemic virtual interactive training system will be used for four weeks

Intervention code:

组别:

对照组

样本量:

206

Group:

Control group

Sample size:

干预措施:

在QQ群推送与全民战疫培训内容一样的资源

干预措施代码:

Intervention:

Push the same resources as the national war epidemic training content in QQ group

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

泸州 

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

重大突发传染病应急准备度

指标类型:

主要指标

Outcome:

emergency preparedness for major emerging infectious disease

Type:

Primary indicator

测量时间点:

干预的第1周和第2周,以及干预后的第1、3、6个月。

测量方法:

调查问卷

Measure time point of outcome:

week one and two of the intervention, and 1, 3, 6 months after the intervention.

Measure method:

questionnaire

指标中文名:

重大突发传染病防控知识

指标类型:

次要指标

Outcome:

Prevention and control knowledge of major emerging infectious disease

Type:

Secondary indicator

测量时间点:

干预的第1周和第2周,以及干预后的第1、3、6个月。

测量方法:

调查问卷

Measure time point of outcome:

week one and two of the intervention, and 1, 3, 6 months after the intervention.

Measure method:

questionnaire

指标中文名:

虚拟交互培训系统评价问卷

指标类型:

次要指标

Outcome:

evaluation of the virtual interactive training system

Type:

Secondary indicator

测量时间点:

干预完成后

测量方法:

问卷调查

Measure time point of outcome:

after the intervention

Measure method:

questionnaire

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机随机

Randomization Procedure (please state who generates the random number sequence and by what method):

computer random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对数据分析者实施盲法

Blinding:

Blind data analysts

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年12月在医院原始数据库共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Sharing the original database in the hospital in December 2022

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用问卷星进行数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Questionnaire was used for data collection and management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-06-14 15:41:46